Market Newsdesk

December 8, 2020 8:59 am

BetterLife adds Next-Gen Psychedelic Therapy to its Pipeline of Drugs

VANCOUVER, Dec. 08, 2020 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech focused on the development and commercialization of revolutionary treatments, today announced the signing of a definitive agreement to acquire 100% of the assets in Transcend Biodynamics LLC (“Transcend”) valued at $10 million in an all-stock transaction (the “Transaction”), for a total of 13,333,333 common shares at $0.75 per share. This non-arm’s length Transaction is subject to the satisfaction or waiver of customary conditions, including regulatory approvals.

Transcend is a research driven biotechnology company committed to addressing unmet mental health needs through the development of patented next generation psychedelic therapeutics including the Lysergic Acid Diethylamide (“LSD”) derivative BOL-148.

LSD has been studied for the treatment of people with a number of psychiatric conditions, including severe depression, alcoholism, and posttraumatic stress disorder throughout the 1950s and 1960s and research is currently experiencing a renaissance, with a number of publications referencing the efficacy of LSD (a Schedule 1 substance) to alleviate or reverse certain mental health conditions.

BOL-148 is a nontoxic second-generation LSD-derived molecule that mimics the therapeutic potential of LSD, without the psychedelic effects or hallucinations. Transcend’s patented process allows for cost effective manufacturing of BOL-148 without the need to make LSD. This makes Transcend the only entity with the ability to synthesize BOL-148 without the regulatory hurdles of handling a Schedule 1 controlled substance.

“We are thrilled to join forces with Transcend,” stated Dr. Ahmad Doroudian, Chief Executive Officer of BetterLife. “Psychedelic therapies have come a long way in recent years, from an idea to be studied to the next great revolution in healthcare, and a massive emerging market and biotech asset class. As we position BetterLife to be a key player in the med-tech sector, we feel that this acquisition will complement our current clinical initiatives in COVID-19 and human papillomavirus.”

“BetterLife is already experienced in bringing innovative molecules to market and is readily poised to bring their strong clinical experience into the emerging psychedelic space. We intend to leverage our intellectual property and experience to design a delivery system for BOL-148 improving its bioavailability and achieving the desired medicinal effects at optimum dosage. We already have the technology and infrastructure in place and believe that we can get BOL-148 ready for clinical testing by Q1 2021,” he concluded.

The Transcend team brings decades of experience and major academic research affiliations. Their CEO Justin Kirkland shares, “We are deeply excited that the time is right to marry our drug development skills with the strong clinical capabilities of BetterLife to ultimately serve the patient in their quest for health.” Transcend’s proprietary library of compounds and development strategy is based on chemical modifications to known and well-understood psychedelics by significantly modifying their pharmacokinetic properties without diminishing their therapeutic potential.

About BetterLife Pharma Inc.

BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer.

For further information please visit www.blifetherapeutics.com.

About Transcend Biodynamics LLC

Transcend is a research focused biotechnology company creating and clinically validating an evolving IP portfolio of novel molecules and drug delivery mechanisms for clinical trials and commercialization. Transcend is focused on developing second generation psychedelic compounds, peptides, pro-drugs, and nutraceuticals to address unmet needs within mental health, wellness and anti-aging industries.

Contact Information:

Ahmad Doroudian, Chief Executive Officer
Email: [email protected]
Phone: 604-221-0595

Dost Mustaq, BDA International Investor Relations Contact
Email: [email protected]
Phone: 646-679-4321

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

December 8, 2020 8:58 am

JDRF Launches First Mass Screening Program for Early-Stage Type 1 Diabetes (T1D) Detection

-T1Detect makes T1D screening easier and more accessible with unrestricted eligibility requirements for at-home testing and financial assistance-

PR Newswire

NEW YORK and RED BANK, N.J., Dec. 8, 2020 /PRNewswire/ — On the heels of National Diabetes Awareness Month, JDRF, the leading global funder of type 1 diabetes (T1D) research, has launched a groundbreaking screening initiative for T1D: T1Detect. Designed to make early detection of T1D easier and more accessible to a broad population, financial assistance is available for the cost of the screening. The initiative is supported by founding sponsor Provention Bio (Nasdaq: PRVB), a biopharmaceutical company focused on intercepting and preventing autoimmune disease.

Detecting T1D before symptoms occur is possible through a blood test when people have two or more diabetes-related autoantibodies and blood sugar levels have become abnormal. Research has proven that 75 percent of people at this stage will become insulin-dependent within five years. Their lifetime risk of clinical disease approaches 100 percent.^ⁱ Approximately 85 percentⁱⁱ of people with T1D have no family history, underscoring the necessity for an all-population screening. T1Detect will be available to people of all ages whether or not they have a family member with T1D.

“T1Detect is the first and only screening program that will enable a broad population to know their risk of T1D,” said Aaron J. Kowalski, Ph.D., President and CEO of JDRF. “This groundbreaking initiative is an important milestone for JDRF because it will increase awareness about early-stage T1D, provide access to crucial education and support for those at risk, and pave the way to ensuring that T1D screening becomes part of universal, clinical preventive services.”

JDRF-funded screening consortia and studies, such as TrialNet, INNODIA, FR1da, and ASK, have shown that identifying at-risk individuals, along with education and monitoring for those found to be positive, reduces the risk of diabetic ketoacidosis, which can be life-threatening, and expands the pool of qualified participants for future trials of disease-modifying therapies. Early detection also enables patients and families to prepare for the onset of clinical disease and a lifetime of insulin administration and glucose monitoring.

“Provention Bio is proud to support JDRF’s screening initiative,” said Ashleigh Palmer, CEO of Provention Bio. “We are committed to working with partners in the T1D community to find new ways to empower patients and doctors with information that could lead to more informed healthcare decisions.”

JDRF has brought together a multi-sectoral collaboration to expand access to T1D screening, including MedIQ, which will provide clinician education, Nuvera Life Science Consulting, which will advise on program design and operations and Enable Biosciences, which will conduct the screenings. Under the JDRF-Beyond Type 1 Alliance, Beyond Type 1 will support community education and awareness. The multi-year initiative is supported by both individual gifts and corporate sponsors.

For more information about the T1Detect initiative and how to obtain an at-home testing kit visit, www.jdrf.org/t1detect. Test kits are only available for shipping within the United States and Puerto Rico.

About JDRF

JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent, and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact and uniting on a national stage to pool resources, passion and energy. We collaborate with academic institutions, policymakers and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF

About Provention Bio, Inc.:

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company’s pipeline includes clinical product development candidates that have demonstrated in clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including diabetes, celiac disease and lupus. Visit ProventionBio.com for more information or follow us on Twitter: @ProventionBio

ⁱ https://care.diabetesjournals.org/content/38/10/1964ⁱⁱ https://www.ncbi.nlm.nih.gov/books/NBK326738/

View original content to download multimedia:http://www.prnewswire.com/news-releases/jdrf-launches-first-mass-screening-program-for-early-stage-type-1-diabetes-t1d-detection-301187886.html

SOURCE JDRF

December 8, 2020 8:58 am

iBio Announces Pricing of $35 Million Public Offering of Common Stock

BRYAN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the pricing of its underwritten public offering of approximately 29.7 million shares of its common stock for gross proceeds of $35.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by iBio. The offering is expected to close on or about December 10, 2020, subject to customary closing conditions. In addition, iBio has granted the underwriter a 30-day option to purchase up to approximately 4.4 million additional shares of its common stock.

Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. Roth Capital Partners acted as financial advisor to iBio.

The underwriter may offer the shares from time to time for sale in one or more transactions on the NYSE American, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. On December 7, 2020, the last sale price of the shares as reported on the NYSE American was $1.50 per share.

iBio anticipates using the net proceeds from the offering to accelerate development of its biotherapeutic and vaccine candidates, in-licensing of biopharmaceutical assets, including, but not limited to, those in oncology, fibrotic, and infectious diseases, and working capital needs and for other general corporate purposes, including acquisitions and investments in other businesses.

The securities described above are being offered by iBio pursuant to a shelf registration statement on Form S-3 previously filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement and the accompanying base prospectus related to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying base prospectus relating to this offering may be obtained, when available, from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th floor, New York, NY 10022; Email: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About iBio, Inc.

iBio is a global leader in plant-based biologics manufacturing. Its FastPharming^® System combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary products on the FastPharming Platform, which include biopharmaceuticals for the treatment of fibrotic and infectious diseases, amongst others. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with the Glycaneering Development Service™ for engineering high-performance recombinant glycoproteins.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding completion of the offering and the anticipated use of proceeds. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, changes to the offering as a result of market conditions or for other reasons, the risk that the offering will not be consummated, the Company’s ability to obtain regulatory approvals for commercialization of its product candidates, including its infectious disease vaccines, or to comply with ongoing regulatory requirements, regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, its ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, its ability to retain its key employees or maintain its NYSE American listing, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended June 30, 2020 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Form 10-Q and Form 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Contact:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
[email protected]

December 8, 2020 8:57 am

HanesBrands Recognized for Sustainability Leadership with First ‘A List’ Score in CDP 2020 Climate Change Report

HanesBrands Recognized for Sustainability Leadership with First ‘A List’ Score in CDP 2020 Climate Change Report

Company is one of four apparel manufacturers on the 270-member A List, ranking in the top 2.8% of 9,600 companies around the globe

WINSTON-SALEM, N.C.–(BUSINESS WIRE)–
HanesBrands (NYSE:HBI) today announced it has earned its first “A List” recognition for leadership in corporate sustainability in the CDP 2020 Climate Change Report.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201208005728/en/

HanesBrands, one of four apparel manufacturers on the 270-member global CDP A List, was recognized for its actions to cut emissions, mitigate climate risks and develop the low-carbon economy. The A score follows two superior A- rankings, placing HanesBrands among the top companies worldwide with eco-friendly operations for the last three years. (Photo: Business Wire)

“We are proud to receive this prestigious recognition for leadership in corporate responsibility and, in particular, addressing climate change,” said Steve Bratspies, HanesBrands CEO. “Consumers around the world are increasingly focused on how companies operate, and this honor shows that consumers can be confident in our commitment to sustainability and feel great about apparel made by HanesBrands.”

CDP’s annual environmental disclosure and scoring process is widely recognized as the gold standard of corporate environmental transparency. A detailed and independent methodology is used by CDP to assess these companies, allocating a score of A to D- based on the comprehensiveness of disclosure, awareness and management of environmental risks and demonstration of best practices associated with environmental leadership, such as setting ambitious and meaningful targets.

“Taking the lead on environmental transparency and action is one of the most important steps businesses can make, and is even more impressive in this challenging year marked by COVID-19,” said Paul Simpson, CEO of CDP. “The scale of the risk to businesses from climate change, deforestation and water insecurity is enormous. Our A List celebrates those companies that are preparing to excel in the economy of the future by taking action today.”

In October, HanesBrands announced wide-ranging 2030 global sustainability goals that include a commitment to science-based environmental targets, a goal of improving the lives of at least 10 million people, and addressing the use of plastics and sustainable raw materials in products and packaging. The goals were launched via a new sustainability website, designed to increase company transparency and reporting on key metrics, including diversity, human rights benchmarks and risk assessments for investors.

Chris Fox, appointed HanesBrands’ chief sustainability officer in November, said: “We’ve made significant progress, but there is much work to do. Our aggressive new 2030 goals, focused on people, planet and product will help create sustainable value for our company, our investors, our consumers, our employees and our communities.”

The company, which has also earned the U.S. Environmental Protection Agency’s Energy Star partner of the year/sustained excellence award for 11 consecutive years, has significantly reduced energy use and carbon emissions since implementing an energy management program in 2007. Recent achievements include optimizing biomass procedures to improve thermal efficiency and replacing HVAC systems, air compressors and lighting with more energy-efficient equipment.

For more details about CDP, its scoring methodology and the full list of A List companies, visit www.cdp.net.

Log on to the HanesBrands Sustainability website (www.hbisustains.com) to learn more about the company’s sustainability initiatives and information.

About CDP

CDP is a global non-profit that drives companies and governments to reduce their greenhouse gas emissions, safeguard water resources and protect forests. Voted number one climate research provider by investors and working with institutional investors with assets of US$106 trillion, we leverage investor and buyer power to motivate companies to disclose and manage their environmental impacts. Over 9,600 companies with over 50% of global market capitalization disclosed environmental data through CDP in 2020. This is in addition to the hundreds of cities, states and regions who have disclosed, making CDP’s platform one of the richest sources of information globally on how companies and governments are driving environmental change. CDP is a founding member of the We Mean Business Coalition. Visit https://cdp.net/en or follow us @CDP to find out more.

About HanesBrands

HanesBrands, based in Winston-Salem, N.C., is a socially responsible leading marketer of everyday basic innerwear and activewear apparel in the Americas, Europe, Australia and Asia-Pacific. The company sells its products under some of the world’s strongest apparel brands, including Hanes, Champion, Bonds, DIM,Maidenform, Bali, Playtex, Lovable, Bras NThings, Nur Die/Nur Der, Alternative, L’eggs, JMS/Just My Size, Wonderbra, Berlei, and Gear for Sports. The company sells T-shirts, bras, panties, shapewear, underwear, socks, hosiery, and activewear produced in the company’s low-cost global supply chain. A Fortune 500 company and member of the S&P 500 stock index (NYSE: HBI), Hanes has approximately 63,000 employees in more than 40 countries. For more information, visit the company’s corporate website at www.Hanes.com/corporate and newsroom at https://newsroom.hanesbrands.com/. Connect with the company via social media: Twitter (@hanesbrands), Facebook (www.facebook.com/hanesbrandsinc), Instagram (@hanesbrands), and LinkedIn (@Hanesbrandsinc).

View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005728/en/

Carole Crosslin: 336-671-3704 (cell)

[email protected]

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Fashion Retail Environment Manufacturing Specialty Textiles

MEDIA:

Logo

Photo

December 8, 2020 8:56 am

Marias Technology Included in AM Best Expert Resources Directory

All companies
listed
in the directory are c
lient
–
recommended
and
verified by AM Best
.

COVINGTON, Ohio, Dec. 08, 2020 (GLOBE NEWSWIRE) — Marias Technology, a provider of software testing and implementation services to the insurance industry, has been accepted into the AM Best Expert Resource Directory. Marias is the first company to be listed under the new category, Insurance Technology Services.

“We’re happy to have been included in the directory and proud to have the recommendation of our clients for inclusion,” said Chris Haines, president and CEO of Marias. “We’re grateful of the recognition of our work by AM Best and for the opportunity to make more insurers aware of our services and the value we provide to their organizations.”

You can see Marias Technology’s listing here. And you can see the authenticating BestMark Badge on the footer of every page of the Marias website.

About Marias Technology

Marias Technology, headquartered in Covington, Ohio, a privately held company, offers insurance technology services to property/casualty insurance companies. Services range from system testing and implementation, to gathering requirements and defining specifications. For more information, please visit www.mariastechnology.com, email [email protected], or call 866-611-2212.

Media Contact:
JoAnna Bennett
201-341-2360
[email protected]

December 8, 2020 8:53 am

Velodyne Lidar Inc. to Participate in D.A. Davidson Semicap, Laser & Optical Virtual Conference

Velodyne Lidar Inc. to Participate in D.A. Davidson Semicap, Laser & Optical Virtual Conference

SAN JOSE, Calif.–(BUSINESS WIRE)–
Velodyne Lidar, Inc. (NASDAQ: VLDR, VLDRW), the first public pure-play lidar company, announces attendance at the D.A. Davidson Semicap, Laser & Optical Virtual Conference on Tuesday, December 15, 2020. Velodyne’s Chief Executive Officer, Dr. Anand Gopalan, and Chief Financial Officer, Drew Hamer, will participate in investor meetings that day. The investor presentation for these meetings is available on Velodyne’s investor relations website at investors.velodynelidar.com.

About Velodyne Lidar, Inc.

Velodyne Lidar (NASDAQ: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit velodyne.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005719/en/

Media Contact:

Sean Dowdall

[email protected]

Investor Contact:

Andrew Hamer

Chief Financial Officer

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Software Hardware Automotive Technology Automotive Manufacturing General Automotive Manufacturing Other Technology

MEDIA:

Logo

December 8, 2020 8:53 am

AAR forms Aviation Safety and Training Oversight Committee

Wood Dale, Dec. 08, 2020 (GLOBE NEWSWIRE) — AAR (NYSE: AIR), a leading provider of aviation services to commercial and government operators, MROs and OEMs is pleased to announce that it has formed an Aviation Safety and Training Committee (the “ASTC”) at the Board of Directors (“Board”) level. The ASTC will be comprised of three independent directors, with retired United States Air Force General Duncan J. McNabb, who last served as the ninth Commander, United States Transportation Command, serving as Chair, and Robert F. Leduc and Jennifer L. Vogel joining him as committee members. The ASTC will assist the Board in the oversight of aviation safety matters relating to AAR’s operations, including training employees, promoting a robust safety culture and helping ensure the delivery of services and products with safety as the highest priority.

“Forming the ASTC at the Board level is the strategic evolution of AAR’s commitment to aviation safety, which is of the utmost importance because of the number of aircraft we touch every day and AAR’s importance to the overall aviation chain of safety,” said David P. Storch, AAR’s Chairman of the Board. “We have proactively established the ASTC to help the Board in continuing to fulfill its fiduciary duties overseeing aviation safety matters and ensuring that AAR continues to have a best in class safety program.”

“The ASTC is comprised of seasoned aviation professionals who will provide valuable oversight and guidance regarding aviation safety matters,” said John M. Holmes, AAR’s Chief Executive Officer. “As a Company, we’re proud and honored that our customers trust us to perform maintenance on their planes and the ASTC will help us deliver safety programs that are on the cutting edge of industry practice.”

“I am delighted to chair the newly formed ASTC at AAR as the Company continues its journey to be best in class in delivering aviation safety,” said Duncan J. McNabb. “The ASTC will provide oversight regarding AAR’s training programs and safety culture, and I look forward to working with AAR leadership, the committee members, and the Board on this important initiative.”

# # #

About AAR
AAR is a global aerospace and defense aftermarket solutions company with operations in over 20 countries. Headquartered in the Chicago area, AAR supports commercial and government customers through two operating segments: Aviation Services and Expeditionary Services. AAR’s Aviation Services include Parts Supply; OEM Solutions; Integrated Solutions; and Maintenance, Repair and Overhaul (MRO) Services. AAR’s Expeditionary Services include Mobility Systems operations. Additional information can be found at www.aarcorp.com.

This press release contains certain statements relating to future results, which are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may also be identified because they contain words such as ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘likely,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘seek,’’ ‘‘should,’’ ‘‘target,’’ ‘‘will,’’ ‘‘would,’’ or similar expressions and the negatives of those terms. These forward-looking statements are based on beliefs of Company management, as well as assumptions and estimates based on information currently available to the Company, and are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or those anticipated, including those factors discussed under Item 1A, entitled “Risk Factors”, included in the Company’s Form 10-K for the fiscal year ended May 31, 2020. Should one or more of these risks or uncertainties materialize adversely, or should underlying assumptions or estimates prove incorrect, actual results may vary materially from those described. These events and uncertainties are difficult or impossible to predict accurately and many are beyond the Company’s control. The Company assumes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. For additional information, see the comments included in AAR’s filings with the Securities and Exchange Commission.

Daniela Pietsch
AAR Corp
+1 630 227 5100
[email protected]

December 8, 2020 8:48 am

Neogen launches new preventative care DNA test, Igenity® Canine Wellness

PR Newswire

LINCOLN, Neb., Dec. 8, 2020 /PRNewswire/ — Neogen Corporation (Nasdaq: NEOG) announced today that it has launched Igenity^® Canine Wellness, a preventative care DNA screening tool for veterinarians.

Genetic background can influence health, physical traits and behavior in dogs. Igenity Canine Wellness addresses this by predicting a percentage of the heritable component for relatively common, actionable diseases. Awareness of genetic risks allows veterinary professionals to make more informed recommendations on diet, diagnostic screening, and lifestyle to enable a longer and happier life for each pet and their family.

“Veterinary professionals can use the knowledge of predisposed risk factors in providing client education and making personalized recommendations related to diet, exercise, and diagnostic screening tests, such as ultrasound or blood work to detect possible health concerns,” said Lindsey Kock, DVM, Neogen’s companion animal market development manager. “Igenity Canine Wellness results will help doctors and staff provide better care for patients in the hospital and equip pet parents to anticipate and prevent health challenges in the future.”

During a veterinary exam, a staff member will use a cytology swab from an Igenity Canine Wellness kit to collect cheek cells from the patient’s mouth. When the veterinary hospital has finished preparing the samples, the kit box is then sent to Neogen Genomics lab for processing. The practice will then receive a genetic risk report that then can be communicated to the pet parent to create a wellness journey to best benefit their canine’s health needs.

Scientists have discovered a great deal since the dog genome was first sequenced in 2004 about the genetics of disease susceptibility, underpinnings of physical traits and even behavior. Much of this research has been driven by studies that utilize non-invasive DNA samples from dogs to investigate the genetic underpinnings of the over 450 potential models for human disease.

“We are just scratching the surface on the underlying genetics in dogs of common conditions such as cancer, allergies, osteoarthritis, obesity and behavior,” said Kock. “The DNA targets for Igenity Canine Wellness are based on published research for common, actionable conditions diagnosed in veterinary medicine.”

“Our genomics team continues to innovate by providing solutions that improve the health and well-being of the animals we care so much for,” said John Adent, Neogen’s president and chief executive officer. “Igenity Canine Wellness will help veterinarians provide a genetic map to pet parents and aid in their quality of service, as well as a dog’s life.”

For more information on Igenity Canine Wellness and list of conditions covered go to www.neogen.com/igenity-canine-wellness/.

Neogen Corporation develops and markets products dedicated to food and animal safety. Neogen’s worldwide genomics operations deliver innovative, affordable DNA testing for the discovery and commercial application of genomic advances that enhance the safety and abundance of life. DNA testing services are provided for food safety, animals, aquaculture, agronomy, forestry and horticulture, as well as supporting the research institutions and organizations serving these industries. See more at www.neogen.com.

CONTACTS:	Product: Lindsey Kock, [email protected]
	Media: Clint Mefford, [email protected]

View original content:http://www.prnewswire.com/news-releases/neogen-launches-new-preventative-care-dna-test-igenity-canine-wellness-301188350.html

SOURCE Neogen Corporation

December 8, 2020 8:48 am

The Cincinnati Insurance Company Expands Innovation Efforts

PR Newswire

CINCINNATI, Dec. 8, 2020 /PRNewswire/ — Cincinnati Financial Corporation (Nasdaq: CINF) announced that its lead property casualty subsidiary, The Cincinnati Insurance Company, plans to accelerate its digital and data transformation to meet the changing needs of independent insurance agents and their clients. The expanded efforts will allow Cincinnati Insurance to grow its internal innovation team focused on enhancing speed and convenience for insurance agents and consumers. The project is being assisted with a $2.5 million JobsOhio R&D Center Grant.

As part of the effort, Cincinnati Insurance plans to further increase its activities at the University of Cincinnati’s 1819 Innovation Hub – UC’s flagship building in the growing Cincinnati Innovation District™. Cincinnati Insurance leased space in the 1819 building in 2018 to serve as the center for all recruiting and engagement activity at UC and for offsite innovation ventures for associates and agents, which complement the company’s innovation initiatives at its Fairfield headquarters.

Brad Purnhagen, Cincinnati Insurance innovation lead, shared, “It was exciting to partner with the JobsOhio team on this process and see how the way we are developing innovation at our company mirrors what is taking place across the state.”

“This assistance from JobsOhio will deepen our dedicated innovation capability and expand the team that supports innovation across our company,” commented, Wendi Bukowitz, vice president and director of Strategic Innovation for Cincinnati Insurance. “Big data, advanced analytic modeling and the rise of InsurTech present opportunities for us to serve independent insurance agents and their customers in new ways, helping them to better identify, understand and manage risk.”

The company will also provide unique learning opportunities for UC students who will be working alongside Cincinnati Insurance associates, developing skills that will support higher-compensated jobs in areas such as data science and artificial intelligence that are aligned with future business requirements.

“As the financial services sector evolves, there is a growing need to strengthen the capabilities of innovative companies like Cincinnati Insurance,” said J.P. Nauseef, JobsOhio president and CEO. “Assisting Cincinnati Insurance’s digital and data transformation will help them to build upon an already outstanding environment as they develop advanced technology and data science career opportunities in Southwest Ohio.”

“With more than $14.2 billion of activity every year, financial services represent one of the key strengths of the Cincinnati region’s economy,” said Kimm Lauterbach, president and CEO of REDI Cincinnati. “The Cincinnati Insurance Company’s announcement marks the latest commitment from an industry leader to the region’s success. Cincinnati Insurance is well-positioned for the future due to their partnership with UC and its placement in the Cincinnati Innovation District.”

About Cincinnati Financial

Cincinnati Financial Corporation offers primarily business, home and auto insurance, our main business, through The Cincinnati Insurance Company and its two standard market property casualty companies. The same local independent insurance agencies that market those policies may offer products of our other subsidiaries, including life insurance, fixed annuities and surplus lines property and casualty insurance. For additional information about the company, please visit cinfin.com.

Mailing Address:	Street Address:
P.O. Box 145496	6200 South Gilmore Road
Cincinnati, Ohio 45250-5496	Fairfield, Ohio 45014-5141

About JobsOhio
JobsOhio is a private nonprofit economic development corporation designed to drive job creation and new capital investment in Ohio through business attraction, retention and expansion. The organization also works to seed talent production in its targeted industries and to attract talent to Ohio though Find Your Ohio. JobsOhio works with six regional partners across Ohio: Dayton Development Coalition, Ohio Southeast Economic Development, One Columbus, REDI Cincinnati, Regional Growth Partnership and Team NEO. Learn more at www.jobsohio.com. Follow us on LinkedIn, Twitter and Facebook.

About REDI Cincinnati
The Regional Economic Development Initiative (REDI) Cincinnati is the first point-of-contact for companies locating or growing in the 16-county region at the heart of southwest Ohio, northern Kentucky, and southeast Indiana. REDI Cincinnati is supported by top business leaders and community partners and staffed by a team of economic development experts who are uniting the Cincinnati region to compete globally.

The future is bright, and we’re building it, right now. Join us at REDICincinnati.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/the-cincinnati-insurance-company-expands-innovation-efforts-301188395.html

SOURCE Cincinnati Financial Corporation

December 8, 2020 8:48 am

Orbit International’s Electronics Group Receives Two New Orders in Excess of $1,200,000

Company’s Power Group 2020 VPX Bookings Exceed Prior Year

HAUPPAUGE, N.Y., Dec. 08, 2020 (GLOBE NEWSWIRE) — Orbit International Corp. (OTC PINK:ORBT), an electronics manufacturer and software solution provider, today announced that its Electronics Group (“OEG”), received two new orders at the beginning of December 2020 for display units and keyboards valued in excess of $1,200,000. Deliveries are scheduled to commence in the third quarter of 2021 and continue through the second quarter of 2022.

In addition, the Company reported that its Power Group (“OPG”) received new orders for its VPX power supplies in the month of November that put its current year to date VPX bookings ahead of its VPX bookings for the entire 2019 year, despite challenges related to testing of the units due to the COVID-19 pandemic.

Mitchell Binder, President and CEO of Orbit International commented, “The two orders received by our OEG were an approximately $500,000 order for displays and an approximately $750,000 for keyboards, both used on major military aircraft programs. These awards add to our relatively strong year of bookings for our OEG and we are hopeful we can add to these awards before year end and complete a solid fourth quarter of bookings.”

Binder added, “Our OPG had another firm month of bookings in November 2020 for its VPX power supplies which pushed year to date bookings to approximately 9.2% ahead of all of 2019 bookings for this product line. We are particularly encouraged that in the last several months, our VPX bookings have significantly increased from the first half of the year, which we believe were adversely affected by the pandemic due to the testing required for new applications. Our increase in VPX and COTS power supply bookings have offset weak bookings from our commercial division which we expected due to the adverse effect the pandemic has had on the industries we serve such as oil and gas exploration and our test and measurement business.”

Orbit International Corp., through its Electronics Group including its new Q-Vio subsidiary, is involved in the development and manufacture of custom electronic device and subsystem solutions for military, industrial and commercial applications through its production facility in Hauppauge, New York. Orbit’s Power Group, also located in Hauppauge, NY, designs and manufactures a wide array of power products including AC power supplies, frequency converters, inverters, VME/VPX power supplies as well as various COTS power sources.

On March 11, 2020, the World Health Organization declared the novel strain of coronavirus (COVID-19) a global pandemic and recommended containment and mitigation measures worldwide. The Company was classified as an essential business by New York State and therefore was exempt from the state’s mandate that all non-essential businesses close their business locations until further notice. In addition, as a member of the Defense Industrial Base (“DIB”), the Company is mandated by the Secretary of Defense to continue to provide the essential products and services required to meet national security commitments to the Federal Government and the U.S. Military. The Company remains open while following guidance from the Centers for Disease Control (“CDC”) to best protect our employees. At this time, the length and severity of the COVID-19 pandemic is still unknown.

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company including, statements regarding our expectations of Orbit’s operating plans, deliveries under contracts and strategies generally; statements regarding our expectations of the performance of our business; expectations regarding costs and revenues, future operating results, additional orders, future business opportunities and continued growth, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although Orbit believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond Orbit International’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact Orbit International and the statements contained in this news release can be found in Orbit’s reports posted with the OTC Disclosure and News service. For forward-looking statements in this news release, Orbit claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Orbit assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

CONTACT
David Goldman
Chief Financial Officer
631-435-8300